4
Changes in Ownership
Edgewise Therapeutics, Inc. Filed Acc 0001853529-26-000002
Chief Scientific Officer sold 5,901 shares at an average $43.73 ($258,042)
- Chief Scientific Officer acquired 12,812 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Russell Alan J · Chief Scientific Officer
Table I: Non-derivative
5 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-08-12 | Exercise or conversion : show line 1 in the form | +5,781 | 30,336 | D | ||
| 2026-08-12 | Exercise or conversion : show line 2 in the form | +7,031 | 37,367 | D | ||
| 2026-08-12 | Sale : show line 3 in the form | −3,238 | $43.68 | $141,428 | 34,129 | D |
| 2026-08-12 | Sale : show line 4 in the form | −2,273 | $43.68 | $99,275 | 31,856 | D |
| 2026-08-12 | Sale : show line 5 in the form | −390 | $44.46 | $17,339 | 31,466 | D |
| Open-market sales · 5,901 sh · avg $43.73 · $258,042 | ||||||
Table II: Derivative
4 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-08-12 | Exercise or conversion : show line 6 in the form Restricted Stock Units | −5,781 | 11,563 | D |
| 2026-08-12 | Exercise or conversion : show line 7 in the form Restricted Stock Units | −7,031 | 21,094 | D |
| 2026-08-12 | Grant or award : show line 8 in the form Restricted Stock Units | +32,500 | 32,500 | D |
| 2026-08-12 | Grant or award : show line 9 in the form Stock Option (Right to Buy) | +65,000 | 65,000 | D |
Loading xslF345X06/primarydocument.xml…